| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹3 0% | 2500% |
| - | - | 4,500 | ₹40 0% | 1250% |
| - | - | 4,700 | ₹5 0% | 1,1250% |
| - | - | 4,800 | ₹3.55 0% | 5,6250% |
| - | - | 4,850 | ₹12.5 0% | 00% |
| - | - | 4,900 | ₹4.5 0% | 9,2500% |
| 2,0000% | ₹336.5 0% | 5,000 | ₹3.5 -33.96% | 10,500-1.17% |
| - | - | 5,050 | ₹8.55 0% | 00% |
| 6250% | ₹244.45 0% | 5,100 | ₹6.2 -23.45% | 11,7500% |
| 6250% | ₹203.7 0% | 5,150 | ₹7.15 -33.48% | 4,00010.34% |
| 3,8750% | ₹334.35 0% | 5,200 | ₹9.3 -35.41% | 27,125-5.65% |
| 1,5000% | ₹283 0% | 5,250 | ₹13.4 -35.73% | 7,625-6.15% |
| 11,875-1.04% | ₹228.85 0% | 5,300 | ₹18.45 -39.8% | 24,250-3.96% |
| 4,875-11.36% | ₹178 3.48% | 5,350 | ₹26.65 -33.2% | 16,5009.09% |
| 23,500-1.57% | ₹149.05 8.08% | 5,400 | ₹38.3 -29.91% | 29,0003.11% |
| 10,375-7.77% | ₹108.8 0.23% | 5,450 | ₹54.2 -24.51% | 10,00045.45% |
| 81,3750.30% | ₹88.95 4.09% | 5,500 | ₹76.25 -23.17% | 28,0009.26% |
| 16,375-5.07% | ₹64.75 4.51% | 5,550 | ₹103.85 -18.22% | 4,125-15.38% |
| 34,875-8.22% | ₹47.5 -0.93% | 5,600 | ₹140.05 -0.77% | 16,0000% |
| 2,875-8% | ₹30.5 -6.44% | 5,650 | - | - |
| 57,50026.02% | ₹23.2 -12.45% | 5,700 | ₹209.55 0% | 1250% |
| 13,375105.76% | ₹15 -23.46% | 5,750 | ₹237.45 0% | 1250% |
| 29,1258.87% | ₹13 -4.05% | 5,800 | ₹300.5 0% | 5000% |
| 7,2509.43% | ₹7.2 -12.19% | 5,900 | ₹388.55 0% | 2500% |
| 15,625-1.57% | ₹5.05 -4.71% | 6,000 | - | - |
| 2,250-35.71% | ₹1.25 -50.98% | 6,100 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
